AI Engines For more Details: Perplexity Kagi Labs You
Non-Small Cell Lung Cancer (NSCLC): Erlotinib is indicated for the treatment of metastatic NSCLC, specifically in patients with tumors that have certain mutations in the epidermal growth factor receptor (EGFR) gene. These mutations make the cancer cells more responsive to EGFR inhibitors like erlotinib. Erlotinib works by inhibiting the activity of EGFR, which is a protein involved in cell growth and division. By blocking EGFR signaling, erlotinib helps slow down or stop the growth and spread of NSCLC tumors.
Pancreatic Cancer: Erlotinib is also approved for the treatment of advanced pancreatic cancer, in combination with another chemotherapy medication called gemcitabine. This combination therapy has been shown to modestly improve overall survival in patients with advanced pancreatic cancer compared to treatment with gemcitabine alone. Erlotinib's mechanism of action in pancreatic cancer is similar to its action in NSCLC, as it inhibits EGFR signaling pathways involved in tumor growth and progression.
Other Cancers: While erlotinib is primarily used in NSCLC and pancreatic cancer, it may also be investigated or used off-label in the treatment of other cancer types, particularly those that overexpress EGFR or have mutations in the EGFR gene.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 2.5 | 0.6 | 3.17 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.7 | 1.2 | 1.25 |
| Allergies | 4.3 | 1.9 | 1.26 |
| Allergy to milk products | 1.9 | 1.3 | 0.46 |
| Alopecia (Hair Loss) | 0.9 | 0.9 | |
| Alzheimer's disease | 4.1 | 5.3 | -0.29 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.4 | 1.1 | 1.18 |
| Ankylosing spondylitis | 3 | 0.8 | 2.75 |
| Anorexia Nervosa | 1.4 | 2.6 | -0.86 |
| Antiphospholipid syndrome (APS) | 1.5 | 1.5 | |
| Asthma | 3.7 | 1.5 | 1.47 |
| Atherosclerosis | 1.8 | 1.5 | 0.2 |
| Atrial fibrillation | 3.2 | 2.1 | 0.52 |
| Autism | 7.7 | 6.7 | 0.15 |
| Autoimmune Disease | 0.9 | 0.7 | 0.29 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.3 | 1.3 | |
| Bipolar Disorder | 2.1 | 1.4 | 0.5 |
| Brain Trauma | 0.3 | 1.1 | -2.67 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.6 | -0.6 | |
| Carcinoma | 2.9 | 1.7 | 0.71 |
| Celiac Disease | 2.9 | 1.8 | 0.61 |
| Cerebral Palsy | 0.9 | 1.3 | -0.44 |
| Chronic Fatigue Syndrome | 4.3 | 5.3 | -0.23 |
| Chronic Kidney Disease | 3 | 2.1 | 0.43 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.1 | 0.18 |
| Chronic Urticaria (Hives) | 1.7 | 1 | 0.7 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 2.5 | 1 | 1.5 |
| Colorectal Cancer | 5.9 | 2.2 | 1.68 |
| Constipation | 1.7 | 0.7 | 1.43 |
| Coronary artery disease | 2.3 | 2.4 | -0.04 |
| COVID-19 | 7.2 | 8.3 | -0.15 |
| Crohn's Disease | 6.6 | 4.1 | 0.61 |
| Cushing's Syndrome (hypercortisolism) | 0.8 | -0.8 | |
| cystic fibrosis | 1.2 | 1 | 0.2 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.2 | 1.4 | 0.57 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 7.9 | 7.3 | 0.08 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.3 | 1 | 0.3 |
| Endometriosis | 3.2 | 1.7 | 0.88 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 3.2 | 1.8 | 0.78 |
| erectile dysfunction | 1.1 | 1.1 | |
| Fibromyalgia | 3.3 | 1.8 | 0.83 |
| Functional constipation / chronic idiopathic constipation | 4.9 | 3.6 | 0.36 |
| gallstone disease (gsd) | 3.6 | 0.7 | 4.14 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 0.9 | 0.22 |
| Generalized anxiety disorder | 2.8 | 1.2 | 1.33 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1 | 0.6 | 0.67 |
| Graves' disease | 1 | 2.4 | -1.4 |
| Gulf War Syndrome | 0.9 | 0.9 | 0 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 3.1 | 1 | 2.1 |
| Heart Failure | 3.2 | 1.7 | 0.88 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 2 | 0.3 | 5.67 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.2 | 3 |
| hyperglycemia | 1.8 | 1.2 | 0.5 |
| Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 4.2 | 2.5 | 0.68 |
| Hypothyroidism | 0.1 | 0.7 | -6 |
| Hypoxia | 3.4 | 3.4 | |
| IgA nephropathy (IgAN) | 1.6 | 1.8 | -0.13 |
| Inflammatory Bowel Disease | 5.9 | 6.6 | -0.12 |
| Insomnia | 1.6 | 2.2 | -0.38 |
| Intelligence | 1.9 | 0.2 | 8.5 |
| Intracranial aneurysms | 1.2 | 0.3 | 3 |
| Irritable Bowel Syndrome | 5.3 | 3.9 | 0.36 |
| ischemic stroke | 2.1 | 1.7 | 0.24 |
| Liver Cirrhosis | 5.5 | 4 | 0.38 |
| Long COVID | 4.5 | 4.2 | 0.07 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.6 | 1.2 | -1 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
| ME/CFS with IBS | 0.7 | 1.9 | -1.71 |
| ME/CFS without IBS | 1.5 | 1.5 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.5 | 0.7 | -0.4 |
| Metabolic Syndrome | 5.4 | 5 | 0.08 |
| Mood Disorders | 7 | 5.8 | 0.21 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.1 | 3 |
| Multiple Sclerosis | 4.9 | 5.1 | -0.04 |
| Multiple system atrophy (MSA) | 0.5 | 0.4 | 0.25 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 1.4 | -3.67 |
| Neuropathy (all types) | 0.8 | 1.6 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.4 | 3.1 | 0.42 |
| NonCeliac Gluten Sensitivity | 0.9 | 0.3 | 2 |
| Obesity | 6.7 | 5.1 | 0.31 |
| obsessive-compulsive disorder | 5.2 | 3.1 | 0.68 |
| Osteoarthritis | 2.7 | 1 | 1.7 |
| Osteoporosis | 2.2 | 1.5 | 0.47 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 6.8 | 6 | 0.13 |
| Polycystic ovary syndrome | 6.4 | 2.5 | 1.56 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.1 | 0.4 | -3 |
| primary biliary cholangitis | 0.9 | 1 | -0.11 |
| Primary sclerosing cholangitis | 1.4 | 2.4 | -0.71 |
| Psoriasis | 2.6 | 2.8 | -0.08 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.3 | 3.2 | 0.66 |
| Rosacea | 0.9 | 0.7 | 0.29 |
| Schizophrenia | 3.5 | 2.3 | 0.52 |
| scoliosis | 0.9 | 0.3 | 2 |
| Sjögren syndrome | 1.7 | 2.2 | -0.29 |
| Sleep Apnea | 1.3 | 1.8 | -0.38 |
| Slow gastric motility / Gastroparesis | 1.2 | 1.2 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 1.7 | |
| Stress / posttraumatic stress disorder | 2.8 | 2.3 | 0.22 |
| Systemic Lupus Erythematosus | 3.3 | 1 | 2.3 |
| Tic Disorder | 1.1 | 0.8 | 0.38 |
| Tourette syndrome | 1 | 0.3 | 2.33 |
| Type 1 Diabetes | 3.6 | 2.2 | 0.64 |
| Type 2 Diabetes | 6.5 | 5.6 | 0.16 |
| Ulcerative colitis | 5.3 | 4.4 | 0.2 |
| Unhealthy Ageing | 3.8 | 2 | 0.9 |
| Vitiligo | 1.9 | 1.3 | 0.46 |
